



FOR IMMEDIATE RELEASE

PlantForm opens office in California

Location provides access to life science and financial communities on the U.S. West Coast

San Francisco, Calif., USA, June 9, 2014—PlantForm Corporation has opened an office in San Francisco, California to introduce the company to the West Coast U.S. market and support discussions with potential partners and venture capital firms in the area.

“Establishing a presence in San Francisco’s Bay Area allows us to develop relationships within the life sciences community in order to foster partnerships and attract financing for the continued evolution of our technology and product pipeline,” said Dr. Don Stewart, PlantForm President and CEO.

The Canadian Trade Commissioner Service has provided valuable support in helping PlantForm explore opportunities and build relationships with VCs and biotech companies in the area, Stewart noted.

“The Consulate General of Canada in San Francisco | Silicon Valley is pleased to welcome PlantForm to the Bay Area,” said Consul General Cassie Doyle. “The new San Francisco location will afford PlantForm the opportunity to showcase innovative Canadian technology to the life sciences community in this region. With a physical presence in the global hub of venture capital and the birthplace of biotech, PlantForm will gain access to globally minded venture firms, and the opportunity to partner with several key multinational pharmaceutical and biotechnology companies. The Trade Commissioner Service is excited to work with high-potential companies like PlantForm by facilitating strategic entry points into the resources of this key market while also highlighting the strengths of the Canadian life sciences ecosystem.”

Contact information for PlantForm’s San Francisco office:

580 California Street, 12th Floor
San Francisco, California
94104, USA
Phone: 415.635.3787

About PlantForm Corporation

PlantForm is commercializing a tobacco-plant-based technology platform for the production of antibody and protein drugs for the treatment of cancer and other devastating diseases. Our plant technology is expected to significantly lower the cost of goods compared to industry-standard mammalian-cell systems for biopharmaceutical production. PlantForm’s **pipeline** includes three biosimilar (generic) monoclonal antibodies for cancer, six innovator antibodies for HIV/AIDS, and a novel protein drug designed to protect against nerve agent exposure.

See a video introducing PlantForm.

-30-



plantformcorp.com

For more information, please contact:

<p>David Cayea Chief Operating Officer david.cayea@plantformcorp.com (519) 381-1505</p>	<p>Stacey Curry Gunn Director of Communications stacey.curry.gunn@plantformcorp.com (519) 827-1131</p>
--	---